logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
TECX
Tectonic Therapeutic, Inc.
31.87
1 x 31.76
1 x 31.87
bid
ask
-
0.93
2.84%
12:00 PM
timesize
Ytd52.78%
1y43.43%
31.71
day range
32.59
14.39
52 week range
39.53
Open32.59Prev Close32.80Low31.71High32.59Mkt Cap618.91M
Vol28.43KAvg Vol204.07KEPS-4.46P/E-7.35Forward P/E-10.16
Beta3.21Short Ratio3.54Inst. Own46.91%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg30.82200-d Avg24.871yr Est74.67

TECX News

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
globenewswire.com
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tecto

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
globenewswire.com
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tec

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
seekingalpha.com
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $81.50 Consensus Price Target from Analysts
defenseworld.net
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $81.50 Consensus Price Target from Analysts

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) have received a consensus rati

Aberdeen Group plc Acquires 785,648 Shares of Tectonic Therapeutic, Inc. $TECX
defenseworld.net
Aberdeen Group plc Acquires 785,648 Shares of Tectonic Therapeutic, Inc. $TECX

Aberdeen Group plc boosted its holdings in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 22

Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC
defenseworld.net
Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC lowered its stake in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of “Moderate Buy” from Brokerages
defenseworld.net
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of “Moderate Buy” from Brok

Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus rating of "Mo

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
seekingalpha.com
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
globenewswire.com
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Busine

WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
globenewswire.com
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
globenewswire.com
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Tr

WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Credo Technology Group Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Credo Technology Group Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarke

Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison
defenseworld.net
Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison

Tiziana Life Sciences (NASDAQ: TLSA - Get Free Report) and Tectonic Therapeutic (NASDAQ: TECX - Get

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $82.17 Average Target Price from Brokerages
defenseworld.net
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $82.17 Average Target Price from Brokerages

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) have received an average ratin

Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point
seekingalpha.com
Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point

Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pul

Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript
seekingalpha.com
Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of T

Tectonic Therapeutic, Inc. ( TECX ) Discusses Positive Topline Results From Phase Ib Part B Trial of

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
globenewswire.com
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect

Tectonic Therapeutic to Participate in September Investor Conferences
globenewswire.com
Tectonic Therapeutic to Participate in September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect

Tectonic (TECX) Q2 R&D Soars 142%
fool.com
Tectonic (TECX) Q2 R&D Soars 142%

Tectonic Therapeutic (TECX -5.35%), a biotechnology company advancing a new generation of biologic m